Pulmonary Fibrosis Treatment Market

Pulmonary Fibrosis Treatment Market Outlook (2024 to 2034)

The global pulmonary fibrosis treatment market size is analyzed to increase from US$ 3.29 billion in 2024 to US$ 6.07 billion by the end of 2034. Worldwide revenue from pulmonary fibrosis treatment is projected to increase at a CAGR of 6.3% from 2024 to 2034.

The lungs play a crucial role in human survival, and living a healthy life becomes significantly challenging when diseases such as pulmonary fibrosis impair their function, making breathing difficult. Pulmonary fibrosis specifically damages the tissues surrounding the air sacs in the lungs, causing them to scar and stiffen over time, which progressively restricts breathing. In today's era of heightened pollution, more individuals are experiencing respiratory issues and seeking treatments for pulmonary fibrosis, thereby creating expanding opportunities in the market.

• The National Institutes of Health (NIH) estimates that approximately 100,000 Americans suffer from idiopathic pulmonary fibrosis (IPF), with between 30,000 and 40,000 new cases diagnosed annually. Globally, IPF affects between 13 to 20 individuals per 100,000 people.
• According to Respiratory Research, there were 4,278 individuals with IPF in the MDV database, while Japan estimated a total of 34,040 patients (mean age: 73 years, 73% male), equating to a frequency of 27 cases per 100,000 people.

Various factors contribute to the development of IPF, predominantly habits such as smoking, infections, certain medications, acid reflux, and exposure to air pollution. Those living near metropolitan areas often contend with increased pollution from urban traffic, which heightens the risk of developing pulmonary fibrosis and drives growth in treatments for the condition.

• In 2022, the United States released approximately 66 million tons of pollutants into the atmosphere, as reported by the Environmental Protection Agency. These emissions contribute significantly to respiratory illnesses, acid rain, ozone and particle production, and visibility impairment.
• According to the World Health Organization (WHO), nine out of ten people breathe air that exceeds WHO guideline limits for contaminants. Individuals with interstitial lung disease (ILD), including pulmonary fibrosis (PF), are particularly vulnerable to the harmful effects of environmental pollution, which may increase the likelihood of developing PF.

In response to the rising incidence of pulmonary fibrosis, various medical therapies have been introduced, including monotherapy, combination therapy, and symptomatic treatments. As urban populations continue to grow, prevalence of pollution-related health issues is projected to rise, presenting opportunities for stakeholders in the pulmonary fibrosis treatment market.

Report Attribute	Detail
Pulmonary Fibrosis Treatment Market Size (2024E)	US$ 3.29 Billion
Forecasted Market Value (2034F)	US$ 6.07 Billion
Global Market Growth Rate (2024 to 2034)	6.3% CAGR
Canada Market Growth Rate (2024 to 2034)	8.5% CAGR
China Market Value (2034F)	US$ 350 Million
North America Market Share (2024E)	71.2%
East Asia Market Share (2034F)	9.5%
Key Companies Profiled	F. Hoffman - La Roche Ltd.; Boehringer Ingelheim; International GmbH; Cipla Ltd (Cipla); Gilead Sciences, Inc.; Bristol-Myers Squibb Company; FibroGen Inc.; Galecto, Inc.

How are Pharmaceutical Companies Capitalizing on Opportunities in This Market?

“Investments in Rigorous Clinical Trials and Regulatory Processes to Obtain Approvals”

Pharmaceutical manufacturers focusing on pulmonary fibrosis medications prioritize building robust pipelines and enhancing patient compliance for upcoming launches. Many companies are actively developing new therapies for this condition, including potential biologics expected to undergo assessment and potentially debut in the coming years. To capitalize on the market, these medication producers engage in diverse research initiatives and navigate regional drug approval processes.

• On August 28, 2023, Lupin, a global pharmaceutical company, announced United States FDA approval for a new generic version of Esbriet (pirfenidone) to treat idiopathic pulmonary fibrosis (IPF).
• Boehringer Ingelheim reported on July 25, 2023, that the FDA had accepted their supplemental New Drug Application (sNDA) for OFEV (nintedanib), exploring its potential for treating fibrosing interstitial lung disease (ILD) in children and adolescents aged 6 to 17.

Industry stakeholders invest significant resources in developing innovative solutions. Regulatory bodies like the FDA actively evaluate these advancements, facilitating the approval of new drugs as medical knowledge progresses.

“Incorporation of Artificial Intelligence in Diagnostics”

Recognizing the severity of the disease, medical professionals from various institutions are increasingly dedicating their efforts to researching more effective treatments with minimal side effects. As our understanding of pulmonary fibrosis advances, the potential for developing improved drugs grows, thereby contributing to pulmonary fibrosis treatment market growth.

• Spearheading a nationwide initiative, researchers at the University of Sydney are investigating genetic links to lung disorders and leveraging artificial intelligence (AI) to enhance early detection and treatment.
• On January 16, 2024, the FDA granted de novo clearance to Imvaria, an AI start-up, for a digital diagnostic tool that analyzes chest CT images to detect signs of idiopathic pulmonary fibrosis.

How Does Poor IPF Diagnosis Affect Market Growth?

“Substantial Cost of Treatment and Limited Research Funding”

One of the primary barriers hindering the expansion of the pulmonary fibrosis market size is the challenge of diagnosis. Idiopathic pulmonary fibrosis (IPF) often mimics other lung conditions, making diagnosis difficult. This can lead to poorer prognoses and delays in treatment. Furthermore, market expansion is hindered by limited treatment options and a lack of guaranteed outcomes.

Due to the rarity of IPF, awareness among the general population is low. This lack of awareness can make it difficult for patients to find healthcare providers with expertise in the disease, resulting in delays in diagnosis and treatment. Moreover, the high cost of therapy places a significant financial burden on patients and their families. All these factors collectively impede market growth.

• Pulmonary fibrosis research indicates that delayed diagnosis due to inadequate IPF treatment is prevalent in the United States. A study found that 98% of 45,000 patients were initially misdiagnosed, with 10% receiving anti-fibrotic medications.

Country-wise Analysis

The market in China is projected to advance at a CAGR of 9.1% from 2024 to 2034. The country is estimated to occupy a pulmonary fibrosis treatment market share of 60.5% in East Asia by the end of 2034.

How are Public and Private Entities Contributing to IPF Treatment in the United States?

“Increasing Public Health Education Campaigns and Significant Research Investments”

Attribute	United States
Market Value (2024E)	US$ 2.31 Billion
Growth Rate (2024 to 2034)	5.8% CAGR
Projected Value (2034F)	US$ 4.06 Billion

The United States is heavily investing in research to understand the mechanisms of pulmonary fibrosis. This includes funding from government agencies like the National Institutes of Health (NIH) and private sector investments aimed at discovering new therapeutic targets and developing novel treatments.

• A recent foundation poll, reported by HealthDay News, found that over 80% of smokers are unfamiliar with pulmonary fibrosis.

This is a concerning statistic for a group disproportionately affected by the disease. Awareness of pulmonary fibrosis is low among both smokers and nonsmokers, with nearly nine out of ten Americans unaware of its symptoms, which include fatigue, shortness of breath, and a persistent dry cough.

What is the Demand Growth Projection for Pulmonary Fibrosis Treatment in South Korea?

“Market Benefitting from Availability of Affordable Skilled Labor for Drug Manufacturing”

Attribute	South Korea
Market Value (2024E)	US$ 12 Million
Growth Rate (2024 to 2034)	10.6% CAGR
Projected Value (2034F)	US$ 33 Million

South Korea has a surplus of skilled labor available at affordable prices, making it highly attractive for outsourcing various projects. Increased funding and budgets, robust R&D efforts, the formation of public and private enterprises, and the attraction of foreign direct investments are key pulmonary fibrosis treatment market trends.

Category-wise Evaluation

Based on distribution channel, the retail pharmacy segment is analyzed to expand at a CAGR of 6.3% from 2024 to 2034.

What are the Primary Benefits of Monotherapy in Treating Pulmonary Fibrosis?

“Fewer Side Effects with Monotherapy and Lower Treatment Cost”

Attribute	Monotherapy
Segment Value (2024E)	US$ 2.38 Billion
Growth Rate (2024 to 2034)	6.3% CAGR
Projected Value (2034F)	US$ 4.38 Billion

Treatment with a single medication at a time is called monotherapy. Pulmonary fibrosis treatment often involves monotherapy using various medications. The three primary options utilized as monotherapy for treating pulmonary fibrosis are pirfenidone, nintedanib, and prednisone (a corticosteroid).

Monotherapy is preferred over other treatment methods due to its advantages, which include fewer side effects, lower costs, better seizure control, and no drug interactions. These benefits drive the market's growth.

Which Indication Accounts for a Substantial Revenue in This Market?

“Idiopathic Pulmonary Fibrosis Holds Significant Share Due to its Progressive Nature”

Attribute	Idiopathic Pulmonary Fibrosis
Segment Value (2024E)	US$ 3.02 Billion
Growth Rate (2024 to 2034)	6.3% CAGR
Projected Value (2034F)	US$ 5.56 Billion

IPF is one of the most common forms of pulmonary fibrosis. Its significant prevalence makes it a major focus for medical research, treatment development, and healthcare resource allocation. There are limited effective treatment options for IPF, which means there is a significant medical need.

• Idiopathic pulmonary fibrosis (IPF) affects up to 207,000 people in the United States alone, according to Lung Org. Additionally, around 55,000 new cases of IPF are diagnosed each year.

Market Landscape

Key players in the pulmonary fibrosis treatment market are engaging in consolidation initiatives, including mergers and acquisitions. A further noteworthy strategy observed in the sector is the growth of business partnerships to enhance pulmonary fibrosis treatment offerings and adapt themselves to the evolving market trends such as cystic fibrosis devices, cutaneous fibrosis treatment, and pulmonary arterial hypertension.

• According to the German News Agency (DPA), a research team based in the United States has created an analytical tool that may help find a treatment for idiopathic pulmonary fibrosis, or IPF, by using a novel method for creating blood vessels from living lung tissue in the lab.

Fact.MR provides detailed information about the price points of key pulmonary fibrosis treatment providers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this latest market report.

Key Segments of Pulmonary Fibrosis Treatment Market Research

• By Therapy :

  • Monotherapy
    • Pirfenidone Therapy
    • Nintedanib Therapy
    • Corticosteroids Therapy
  • Combination Therapy
    • Pirfenidone & Corticosteroid
    • Nintedanib & Corticosteroid
    • Pirfenidone & Antitussive
    • Others
  • Symptomatic Treatment

• By Indication :

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Familial PF
  • Others

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

• By Region :

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa